Liraglutide is shown to inhibit inflammatory response and delay DN progression in diabetic rat models by reducing the expression of ERK1/2 and JNK phosphorylation and downregulating the nuclear NF-кB expression.18 In the diabetic setting, increased mitochondrial ROS (mROS) can bring structural and functional damage to the kidneys, resulting in the development and progression of DN. Here, MAPK8 is linked to liver dysplastic nodule.